Impact of an Intravenous Trimethoprim/Sulfamethoxazole Shortage on Treatment Outcomes Among HIV-Infected Patients with Pneumocystis jirovecii Pneumonia

BACKGROUND: Trimethoprim/sulfamethoxazole (TMP/SMX) is the recommended first-line treatment for human immunodeficiency virus (HIV)-infected patients with Pneumocystis jirovecii pneumonia (PJP).However, in June 2010, the lone manufacturer of intravenous (IV) TMP/SMX in the United States stopped produ...

Descripción completa

Detalles Bibliográficos
Autores principales: Dilworth, Thomas J., Ibrahim, Omar M., Mercier, Renée-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441019/
https://www.ncbi.nlm.nih.gov/pubmed/25443518
http://dx.doi.org/10.18553/jmcp.2014.20.12.1246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441019/
https://www.ncbi.nlm.nih.gov/pubmed/25443518
http://dx.doi.org/10.18553/jmcp.2014.20.12.1246

Ejemplares similares